Last reviewed · How we verify
DAT-2645 tablet
At a glance
| Generic name | DAT-2645 tablet |
|---|---|
| Sponsor | Danatlas Pharmaceuticals Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAT-2645 tablet CI brief — competitive landscape report
- DAT-2645 tablet updates RSS · CI watch RSS
- Danatlas Pharmaceuticals Co., Ltd portfolio CI